Search Results

Verseon International Corporation, the company leading a technology-driven transformation of the pharmaceutical industry, announces that it has acquired Edammo, Inc.

Verseon is pleased to announce that the European Patent Office has granted intellectual property protection covering novel chemical matter developed by Verseon that includes the company’s plasma kallikrein inhibitors (PKIs).

Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.

What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.

Verseon Corporation announces that all resolutions put to shareholders were duly passed during the Annual General Meeting (“AGM”) held on November 5, 2018 at 14:00 PDT.